The company’s MRIdian offers more accurate radiotherapy for cancer patients but they won’t have the field to themselves. Worries about the viability of the MRIdian are unfounded as a competitor takes a financial stake in the company. However, the case for investors is far from clear cut as order growth slows and losses, cash bleed, […]
Entries Tagged as 'VRAY'
January 29th, 2020 · Comments Off on ViewRay’s MRIdian Is Promising, But Losses Mount